Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O96007
UPID:
MOC2B_HUMAN
Alternative names:
MOCO1-B; Molybdenum cofactor synthesis protein 2 large subunit; Molybdenum cofactor synthesis protein 2B; Molybdopterin-synthase large subunit
Alternative UPACC:
O96007; Q6IAI3
Background:
The Molybdopterin synthase catalytic subunit, known by alternative names such as MOCO1-B and Molybdopterin-synthase large subunit, plays a pivotal role in the biosynthesis of molybdopterin. This process is crucial for the activation of molybdenum-containing enzymes, which are vital for various biological reactions.
Therapeutic significance:
Molybdopterin synthase catalytic subunit's dysfunction is directly linked to Molybdenum cofactor deficiency, complementation group B, a severe metabolic disorder marked by early childhood mortality. Understanding its mechanism could lead to groundbreaking treatments for this lethal condition.